A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults

Vaccine

Volumn 29, Issue 50, 2011, Pages 9391-9397

  Block, Stan L ^a   Yi, Tingting ^b   Sheldon, Eric ^c   Dubovsky, Filip ^b   Falloon, Judith ^b  

^a Kentucky Pediatric Research Institute   (United States)

^b MEDIMMUNE   (United States)

^c MIAMI RESEARCH ASSOCIATES   (United States)

Author keywords

Clinical trial; Immunogenicity; Influenza vaccine; Noninferiority; Quadrivalent

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CONTROLLED STUDY; COUGHING; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FIBULA FRACTURE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOUTH PAIN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RHINORRHEA; SIDE EFFECT; SNEEZING; SORE THROAT; SYMPTOM; TIBIA FRACTURE; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 80855132907     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.109     Document Type: Article

References (41)

1. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
2. Barr I.G., McCauley J., Cox N., Daniels R., Engelhardt O.G., Fukuda K., et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 2010, 28:1156-1167.
3. World Health Organization Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Wkly Epidemiol Rec 2010, 85:81-92.
4. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(Suppl. 4):D45-D53.
5. Treanor J. Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 2004, 350:218-220.
6. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28:2149-2156.
7. Hite L.K., Glezen W.P., Demmler G.J., Munoz F.M. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis 2007, 11:40-47.
8. Peltola V., Ziegler T., Ruuskanen O., Influenza A. B virus infections in children. Clin Infect Dis 2003, 36:299-305.
9. Pitman R.J., Melegaro A., Gelb D., Siddiqui M.R., Gay N.J., Edmunds W.J. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007, 54:530-538.
10. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
11. Sullivan K.M., Monto A.S., Longini I.M. Estimates of the US health impact of influenza. Am J Public Health 1993, 83:1712-1716.
12. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
13. Olson D.R., Heffernan R.T., Paladini M., Konty K., Weiss D., Mostashari F. Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med 2007, 4:e247.
14. Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175:59-68.
15. Centers for Disease Control and Prevention. Situation Update:Summary of Weekly FluView. Centers for Disease Control and Prevention. Available from: [accessed 10.10.11]. http://www.cdc.gov/flu/weekly/summary.htm.
16. Hoffmann E., Mahmood K., Chen Z., Yang C.F., Spaete J., Greenberg H.B., et al. Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J Virol 2005, 79:11014-11021.
17. Jin H., Lu B., Zhou H., Ma C., Zhao J., Yang C.F., et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306:18-24.
18. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15:295-323.
19. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
20. Seidman J.C., Richard S.A., Viboud C., Miller M.A. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses 2011, doi:10.1111/j.750-2659.011.00268.x.
21. Block S.L., Reisinger K.S., Hultquist M., Walker R.E. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007, 51:4001-4008.
22. Basha S., Hazenfeld S., Brady R.C., Subbramanian R.A. Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011, 72:463-469.
23. Treanor J.J., Kotloff K., Betts R.F., Belshe R., Newman F., Iacuzio D., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.
24. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59:1-15.
25. US Food and Drug Administration. Package Insert - FluMist® Influenza Vaccine Live, Intranasal. Available from: [accessed 10.10.11]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123743.pdf.
26. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
27. World Health Organization. Manual on animal influenza: diagnosis and surveillance. Available from: [accessed 10.10.11]. http://www.who.int/csr/resources/publications/influenza/en/whocdscsrncs20025rev.pdf.
28. Influenza vaccine: recommendation of the Public Health Service Advisory Committee on Immunization Practices. Ann Intern Med 1978; 89:657-9.
29. Couch RB. Vaccines and Related Biological Products Advisory Committee Meeting. Background and presentation of possible vaccine options. Available from: [accessed 10.10.11]. http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4282S2_11.ppt.
30. Reed C, Meltzer M, Finelli L, Fiore A. Public health impact of including two influenza B strains in seasonal influenza vaccines. Available from: [accessed 10.10.11]. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm176375.htm.
31. Centers for Disease Control and Prevention. Past Weekly Surveillance Reports. Available from: [accessed 10.10.11]. http://www.cdc.gov/flu/weekly/pastreports.htm.
32. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
33. He X.S., Holmes T.H., Zhang C., Mahmood K., Kemble G.W., Lewis D.B., et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006, 80:11756-11766.
34. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
35. Lee M.S., Mahmood K., Adhikary L., August M.J., Cordova J., Cho I., et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 2004, 23:852-856.
36. Breiman R.F., Brooks W.A., Goswami D., Lagos R., Borja-Tabora C., Lanata C.F., et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 2009, 27:5472-5479.
37. Nolan T., Bernstein D.I., Block S., Hilty M., Keyserling H.L., Marchant C., et al. Safety and immunogenicity of concurrent live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines in infants 12-15 months of age. Pediatrics 2008, 121:508-516.
38. Nolan T., Lee M.S., Cordova J.M., Cho I., Walker R.E., August M.J., et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 2003, 21:1224-1231.
39. Zangwill K.M., Droge J., Mendelman P., Marcy S.M., Partridge S., Chiu C.Y., et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 2001, 20:740-746.
40. Izurieta H.S., Haber P., Wise R.P., Iskander J., Pratt D., Mink C., et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005, 294:2720-2725.
41. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282:137-144.